tracking

Healthcare’s Once-in-a-Generation Disruption

The cost of healthcare in the United States continues to rise and the availability continues to decline. Healthcare spending accounts for 18% of U.S. GDP, and the costs in the U.S. are the highest in the world, increasing 130% in just the last decade. With this complexity comes an opportunity for entrepreneurs, innovators, and investors. iSelect is focused on finding technologies and innovations that reduce costs, increase accessibility, and improve quality of care.

Our Companies | Our Network | Join Our Network | News

iSelect Portfolio Companies

iSelect focuses on early-stage healthcare companies that are poised to help push the next healthcare revolution forward. We deliberately invest in companies that can make a positive impact on our society, as well as on the bottom line.

Cocoon Biotech, Inc.

Fibroin is an insoluble protein that is responsible for silk’s structure and tensile strength. Additional physical properties include tunable viscosity, anti-inflammatory, and wound healing attributes. Cocoon’s fibroin is expected to yield substantial improvements in use-cases such as bio-preservatives, drug or small/molecule delivery, natural lubricants, and hydrogels across numerous industries including human and animal health, agriculture, and consumer products. Learn more…

Company Website

Nix, Inc.

Nix is developing a wearable, single-use patch that monitors hydration in real-time, without the need for a power-source or companion device/app. Using a proprietary hydrogel developed at Harvard University, Nix’s biosensor detects changes in an individual’s sweat as he or she dehydrates and rehydrates, including the level of electrolyte losses, indicating when to drink, what to drink, and how much to drink. Dehydration is particularly problematic among athletes, military personnel, laborers, and the elderly, causing a reduction in performance and an increase in hospitalization. Nix’s initial target is the estimated 60 million U.S. amateur and professional athletes, which the Company believes represent a $4.8 billion total addressable market for its product. Learn more…

Company Website

Flywheel Exchange, LLC

Flywheel offers a SaaS platform that provides cloud-scale data management and computational analysis. Learn more…

Company Website

MOBILion Systems

MOBILion Systems Inc. has developed technology that can separate and identify previously undetectable, clinically significant molecules within minutes, enabling far more accurate disease diagnosis, biomarker discovery, drug discovery, and clinical trial design among other potential applications. Today, liquid-chromatography mass-spectrometry (LC-MS), sometimes used with ion mobility (LC-IM-MS), instruments are most commonly used for molecular isolation and identification, where the LC and IM components isolate metabolites while the MS component identifies them. Due to physical constraints, LC-IM is limited in its ability to isolate molecules that are small, chemically similar or in limited quantity. In addition, LC-MS and LC-IM-MS are complicated, time consuming processes with limited throughput. As such, the widespread use of LC-MS and LC-IM-MS is limited, particularly in clinical settings. MOBILion?s Structures for Lossless Ion Manipulation (SLIM) technology eliminates the physical constraints encountered by LC and LC-IM, enabling unprecedented throughput, ion separation and ion identification, even in isomers with the same molecular structures. These advancements enable MOBILion to develop simpler instruments with significantly higher degrees of sensitivity and accuracy, while maintaining a low cost and high throughput (hours instead of weeks or months), greatly increasing the commercial viability of the technology.  Learn more…

Company Website

Shield Diagnostics Corp.

Antibiotic resistance is a rapidly growing problem for the treatment of infections, as the broad spectrum use of antibiotics has substantially increased the rate of resistance development. Consequentially, the number of deaths due to antibiotic resistance has increased 7x in the past 5 years and is projected to reach 1.1 million by 2023. Coincidentally, the number of new antibiotics being developed has dropped significantly, as antibiotic development struggles from lack of economic incentives. Therefore, there is a growing need for diagnostic technologies that more accurately determine which antibiotics should be used and when. Shield Diagnostics has developed an infectious disease diagnostics platform to combat the onset of antibiotic resistance, helping clinicians diagnose and treat antibiotic resistant infections at orders of magnitude more accurately, more quickly and at a lower cost. Shield Diagnostics’ tests are currently being used to diagnose antibiotic resistance in gonorrhea (Target-NG) and the Company is developing a diagnostic test that can diagnose infections causing sepsis (Target-SP). Shield Dx’s platform can identify an infection in 3-5 hours, which is incredibly important for diseases like sepsis where turnaround time is crucial to patient survival (1 extra hour to appropriate antibiotic treatment increases mortality 7%). Learn more…

Company Website

Molecular Assemblies

Molecular Assemblies is developing an enzymatic DNA synthesis platform technology, enabling new products in industrial synthetic biology, personalized therapeutics, precision diagnostics, data storage, nanotechnology and more. Molecular Assemblies’ novel enzymatic DNA synthesis platform has the potential to fundamentally transform how we write genetic building blocks with applications across food, healthcare, energy, and beyond.  Learn more…

Company Website

Healionics, Inc.

Healionics, Inc. has developed a novel bio-material called STAR, that features strong anti-infective properties and significant reduction in the formation of scar tissue around implanted medical devices coated with the material. Learn more…

Company Website

SciBac, Inc.

SciBac is developing a platform technology called MERGE that enables the Company to efficiently combine desired traits of two microbes into one stable hybrid organism through lab-induced directed evolution. Learn more…

Company Website

GeneMatters, LLC

GeneMatters is a digital health platform that provides scalable, on-demand genetic counseling to meet the rapidly growing demand for genetic services. Learn more…

Company Website

Cofactor Genomics, Inc.

Cofactor Genomics uses proprietary RNA sequencing (“RNA-Seq”) technology and machine learning algorithms to diagnose disease. Learn more…

Company Website

Entac Medical, Inc.

Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Previs Audio Spectral Analysis. Their first product is used to predict post operative ileus after GI surgeries. Learn more…

Company Website

Neuros Medical, Inc.

Neuros Medical, a medical device company, develops an electrical nerve block to treat chronic pain for conditions including neuroma/residual limb pain and chronic post-surgical pain. Learn more…

Company Website

Indalo Therapeutics

Indalo is a pharmaceutical company developing life-changing treatments for fibrotic diseases. Learn more…

Company Website

Epharmix, Inc.

Epharmix is a healthcare software company substantially reducing the cost of care for chronic diseases using text messaging. Learn more…

Company Website

Gila Therapeutics, Inc.

Gila Therapeutics is developing a treatment for obesity using naturally occurring hormones known to induce satiety, leading to weight loss. Learn more…

Company Website

Euclises Pharmaceuticals, Inc.

Euclises Pharmaceuticals is developing novel enzyme (COX-2) inhibitors designed to increase the effectiveness of chemotherapy safely Learn more…

Company Website

Immunophotonics, Inc.

Immunophotonics has developed a minimally invasive therapeutic cancer vaccine for the treatment of metastatic solid tumors. Learn more…

Company Website

Meet Our Selection Committee

Our Healthcare Selection Committee consists of industry and subject matter experts who help guide iSelect’s investment decisions. With firsthand experience and a true pulse on the industry, we consider these individuals key to our success in finding and investing in healthcare innovation.

Tiffany Osborn holds a Bachelor’s of Science Degree in Biology with a minor in Chemistry from University of Houston in Houston, Texas. She earned her medical degree from University of Texas Health Science Center in San Antonio, Texas prior to completin …

Read full bio >

Ruchir Sehra, M.D., is a medtech executive with extensive experience in early (private), mid (public), and late stage (acquisition) medical device companies in various health and disease areas. Dr. Sehra currently serves as the CEO and President of Res …

Read full bio >

Surekha Trivedi is VP Strategic Development at Danaher. She is a Senior Strategy, M&A, and Product Development Executive with a deep understanding of the life sciences, diagnostics, and healthcare markets. Recognized as a strategy expert and thought le …

Read full bio >

Jill Davies is Co-Founder and Chief Executive Officer for GeneMatters. Jill has more than 20 years’ experience in the genetics field, with leadership in clinical services, telehealth, product development, business development and operations. Prior to f …

Read full bio >

Vice President of Research at Matatu, Nathan McNulty is microbiologist with a passion for addressing complex problems in healthcare, nutrition, and agriculture using innovative technologies, carefully conducted science, and teamwork.

Read full bio >

Jin-Moo Lee, MD, PhD, is Professor of Neurology, Radiology, and Biomedical Engineering; and Head of the Cerebrovascular Disease Section in the Department of Neurology; Co-Director of the Stroke and Cerebrovascular Center at Barnes-Jewish Hospital/Washi …

Read full bio >

Emily Fassi is a board-certified genetic counselor with experience counseling adults and children about genetic diagnoses and predisposition to genetic conditions. She currently works at the Mountain States Tumor Institute with patients who have a pers …

Read full bio >

Dr. David Messina has spent the last 20 years in computational biology and genetics. He worked on the Human Genome Project at Washington University in Saint Louis, mapped disease genes at the University of Chicago, and co-developed the first comprehens …

Read full bio >

Dr. Bruce German is a Professor and Chemist of Food Science and Technology at the University of California, Davis and researches the role of fats and other components in the diet. He develops ways to assess health and metabolism in response to foods. M …

Read full bio >

Jean Roberson

Jean Roberson is CFO of Appistry, a big data analytics company focused on supporting precision medicine and next generation healthcare. She has over 25 years of experience in all areas of finance from early-stage venture-funded companies to large corpo …

Read full bio >

A regulatory professional with over 27 years of experience in the medical products industry, Melissa currently serves as Founder, President and CTO at Graematter, Inc. and Senior VP Regulatory at Topera. Specialties include regulatory intelligence rese …

Read full bio >

Andrew Daniels

Andy Daniels is the founder and Chief Executive Officer of Daniels Trading. He oversees the daily operations of the firm, while maintaining his own trading, as well as advising several selected, long-established customers. In everything he does, Andy s …

Read full bio >

Dr. Paul D. Olivo, M.D., Ph.D., has been the Chief Scientific Officer of Apath, LLC since 2000 and served as its President. Dr. Olivo is an Entrepreneur-in-Residence at BioGenerator, where he previously served as a Senior Entrepreneur-in-Residence. He …

Read full bio >

Bobby Sandage

Bobby Sandage is currently President and CEO of Euclises, Chairman of the Board of Immunophotonics, member of the board of directors of EDIS, and a member of the Cultivation Capital life sciences fund investment committee. He was formerly President and …

Read full bio >

Lila Solnica-Krezel is professor and head of Developmental Biology at Washington University St. Louis, School of Medicine.  She is currently investigating the cellular and molecular genetic mechanisms underlying vertebrate gastrulation, which has pract …

Read full bio >

Gian Cavallini oversees the development and execution of Advanced ICU Care’s medical staffing growth strategy and leads the implementation of various initiatives to position the company for continued growth. His expertise in development and operations, …

Read full bio >

Don Imholz

Mr. Don Imholz is a business executive/leader with diverse experience in Operations and IT, extensive Board involvement, and a strong track record of creating sustainable competitive advantage. His expertise in cybersecurity, big data, digital transfor …

Read full bio >

Michael Beat

Presently leading Arch Cancer Care as Medical Director, Dr. Beat is a local expert in collaborative prostate cancer management. At a national level, he contributes to physician leadership committees within the US Oncology Network. Having earned an exec …

Read full bio >

Mr. Beuttenmuller possesses over 30 years experience in Corporate Finance with Emerson Electric, Esse Health, Essence Healthcare and Innovare. He is experienced in financial analysis, risk management, mergers and acquisitions, new business development, …

Read full bio >

Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation at UUniversity of Iowa Roy J. and Lucille A. Carver College of Medicine and former Professor of Medicine and Genetics at Washington University School of Medicine …

Read full bio >

Dr. John Talley, Chief Science Officer for Euclises Pharmaceuticals and SARmont,  brings over thirty years experience and a record as one of the world’s most successful medicinal chemists. He is best known as the co-inventor of the blockbuster COX-2 in …

Read full bio >

Bryce Rutter

Dr. Rutter is founder and CEO of Metaphase Design Group, a design firm serving industrial, commercial and consumer product and packaging clients internationally.  He is an acknowledged specialist in ergonomic product design and a leading worldwide expe …

Read full bio >

Mark has served as ProteoSense’s CEO since 2013. Previously, Mark served as CEO/COO of several startups, including Assurex Health (2006-09). Mark earned a B.S. in Electrical Engineering from the Univ. of Dayton and an M.S. Electrical Engineering from O …

Read full bio >

Dr. Panagos is a Professor of Emergency Medicine and Neurology at Washington University in St Louis. He is a 1987 graduate of Dartmouth College. In 1994, he completed his medical education at Emory University. Following a year of surgical training at N …

Read full bio >

Before joining OTMIR in 2016, Brian Buntaine worked for more than 15 years in the life sciences industry. He began his career as a lab manager at Washington University in St. Louis. In 2003, Brian joined Sigma-Aldrich where he worked as a research and …

Read full bio >

Dr. Raghavan brings several years of experience managing preclinical safety and efficacy studies for biologicals and small molecule therapeutics and managing strategic alliances with biotech and pharmaceutical companies. His expertise includes postdoct …

Read full bio >

Edwards was employed for 42 years in the pharmaceutical and life sciences arenas. From 1990 to 2010, he held Regulatory Affairs positions of increasing responsibility at TAP/Takeda Global Research & Development Center, Lake Forest, Illinois.  Betwe …

Read full bio >

Michael Nichols

Michael Nichols, Ph.D. presently serves as an investor and C level management for various startups. He serves as an Analyst for Vinlogx, a platform that acquires, stores, and analyses internal vehicle information enabling solutions across multiple auto …

Read full bio >

David Christenson

David Christenson joined BioGenerator as an Entrepreneur-in-Residence in 2015 focusing primarily on healthcare and specifically in information technology, care delivery and payment, and services. Over a 30-year career, David has developed a substantive …

Read full bio >

Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine

Read full bio >

Renaldo Cataldo

An accomplished senior executive with start-ups, growth, and turn-around organizations, Renato developed a healthcare technology corporation, HealthTech Solutions, from a small start-up of 3 people to a national provider of technical solutions to healt …

Read full bio >

Join Our Healthcare Innovation Network

Join the thousands of entrepreneurs, investors, and industry professionals driving the future of healthcare.

Resources and News

RNA Is Becoming the New DNA, Opening New Doors in Medicine

RNA Is Becoming the New DNA, Opening New Doors in Medicine

If a person’s DNA is the roadmap of their lifetime health, their RNA is more of a real-time barometer, recording what happens in their body on a minute-by-minute basis. Our DNA stores and transfers genetic information, but remains little changed throughout our lives. At best, it can tell us about the probability we will someday develop various diseases — whether or not we will get cancer, for instance, or be susceptible to diabetes or heart disease — but it  can’t tell us much about our current health.

read more
What iSelect Is Looking For in the Companies It Invests In

What iSelect Is Looking For in the Companies It Invests In

So people ask me what the optimal, or perfect, iSelect investment opportunity looks like. And there's a scientific, or a finance type of answer that I can give you that we're looking for a company that has an opportunity to have a 10 times return to our investor, or...

read more
Gila Therapeutics Completes Phase I Clinical Trial

Gila Therapeutics Completes Phase I Clinical Trial

Obesity drug developer, Gila Therapeutics, recently took a big step toward FDA approval for its new weight control treatment, completing its Phase I clinical trial in August. Gila is developing a novel intra-oral delivery of PYY, a well-known satiety hormone, to help...

read more
DNA, RNA and the Coming Reality of Personalized Medicine

DNA, RNA and the Coming Reality of Personalized Medicine

Medicine has always been a science of averages. Most people in the population tend to suffer from most of the same diseases, and most of those diseases respond to most of the same treatments. If one therapy doesn’t work, doctors always have other drugs and other...

read more
Resistant Hypertension: Ending the Death Sentence

Resistant Hypertension: Ending the Death Sentence

Physicians have been fascinated with blood and the circulatory system for hundreds of years. Records dating back to early Roman times prove that bloodletting was in wide use as a treatment for disease at least 2,000 years ago, and leeches have been used in medicine...

read more